Other Events ·
NeuroSense Therapeutics says Phase 2b ALS study hits primary endpoint, showing significant TDP-43 reduction
NRSNNeuroSense Therapeutics Ltd.
On June 29, 2026, NeuroSense Therapeutics announced that its Phase 2b study for Amyotrophic Lateral Sclerosis (ALS) achieved its primary endpoint, demonstrating a statistically significant reduction of TDP-43, a defining pathological hallmark of the disease. The company incorporated the results into several existing Registration Statements on Form S-8 and Form F-3. NeuroSense Therapeutics is a biotechnology company developing therapeutics for neurological disorders.